Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Quetiapine XR in schizophrenic patients with cannabis abuse
2008-000766-23Phase 3Completed
- Sponsor
- Hannover Medical School
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of quetiapine in schizophrenia, cannabis-induced psychosis (CIPD) and cannabis use disorder (CUD), sponsored by Hannover Medical School. Primary endpoint: PANSS total score reduction at 3 months. Started May 2008; status: completed.
02
Drugs
quetiapine
03
Conditions
schizophreniacannabis-induced psychosis (CIPD)cannabis use disorder (CUD)
Beyond the preview
Go deeper on 2008-000766-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000766-23.